Tokyo Tape
Sign in
← Immuno-Biological Laboratories

Half-year report · Q2

4570.TEDINET S100URML
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥444m2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥817m2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥366m2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥68m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥13m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥64m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥125m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥31m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥64m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥30m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥72m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥187m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥27m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥72m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥27m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.6bnat 2024-09-30Cons.Assets
Total assets¥1.6bnat 2024-03-31Cons.Assets
Total assets¥1.4bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥309mat 2024-09-30Cons.Liabilities
Total liabilities¥353mat 2024-03-31Cons.Liabilities
Net assets / equity¥1.3bnat 2024-09-30Cons.Net assets
Net assets / equity¥1.3bnat 2024-03-31Cons.Net assets
Net assets / equity¥1.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥731mat 2024-09-30Cons.Cash and deposits
Cash and deposits¥734mat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥666mat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥675mat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥566mat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥562mat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥77m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥134m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥7m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥44m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥24m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥9m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥39m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥991,0002023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥3m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥7.682024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥20.052023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥2.882023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio81.2%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio78.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio77.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentrevenue2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentrevenue external2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentsegment profit2024-04-01 → 2024-09-30¥723,000
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥441m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥441m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥67m
—segment totalrevenue2024-04-01 → 2024-09-30¥444m
—segment totalrevenue external2024-04-01 → 2024-09-30¥444m
—segment totalsegment profit2024-04-01 → 2024-09-30¥68m
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentrevenue2023-04-01 → 2023-09-30¥2m
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentrevenue external2023-04-01 → 2023-09-30¥2m
jpcrp040300-q2r_E00986-000Cosmeticsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥3m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥363m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥363m
jpcrp040300-q2r_E00986-000Immunity Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥16m
—segment totalrevenue2023-04-01 → 2023-09-30¥366m
—segment totalrevenue external2023-04-01 → 2023-09-30¥366m
—segment totalsegment profit2023-04-01 → 2023-09-30¥13m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 437
ItemContextValueUnit
Capital stockPrior1YearInstant50000000JPY
Capital stockCurrentQuarterInstant50000000JPY
Capital surplusPrior1YearInstant1040407000JPY
Capital surplusCurrentQuarterInstant1040407000JPY
Retained earningsPrior1YearInstant176894000JPY
Retained earningsCurrentQuarterInstant248406000JPY
Treasury stockPrior1YearInstant-1990000JPY
Treasury stockCurrentQuarterInstant-1990000JPY
Shareholders equityPrior1YearInstant1265311000JPY
Shareholders equityCurrentQuarterInstant1336823000JPY
Net assetsPrior1YearInstant1265311000JPY
Net assetsCurrentQuarterInstant1336823000JPY
Liabilities and net assetsPrior1YearInstant1618582000JPY
Liabilities and net assetsCurrentQuarterInstant1645596000JPY
Net salesPrior1YTDDuration365516000JPY
Net salesCurrentYTDDuration444127000JPY
Cost of salesPrior1YTDDuration150762000JPY
Cost of salesCurrentYTDDuration164149000JPY
Gross profitPrior1YTDDuration214753000JPY
Gross profitCurrentYTDDuration279977000JPY
Selling general and administrative expensesPrior1YTDDuration201453000JPY
Selling general and administrative expensesCurrentYTDDuration211975000JPY
Operating incomePrior1YTDDuration13300000JPY
Operating incomeCurrentYTDDuration68002000JPY
Interest income noiPrior1YTDDuration47000JPY
Interest income noiCurrentYTDDuration91000JPY
Foreign exchange gains noiPrior1YTDDuration8299000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration6697000JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration－JPY
Insurance premiums refunded cancellation noiPrior1YTDDuration87000JPY
Insurance premiums refunded cancellation noiCurrentYTDDuration359000JPY
Electricity sale income noiPrior1YTDDuration1327000JPY
Electricity sale income noiCurrentYTDDuration1261000JPY
Royalty income noiPrior1YTDDuration632000JPY
Royalty income noiCurrentYTDDuration583000JPY
Other noiPrior1YTDDuration823000JPY
Other noiCurrentYTDDuration152000JPY
Non operating incomePrior1YTDDuration17915000JPY
Non operating incomeCurrentYTDDuration2448000JPY
Interest expenses noePrior1YTDDuration533000JPY
Interest expenses noeCurrentYTDDuration619000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration5568000JPY
Other noePrior1YTDDuration43000JPY
Other noeCurrentYTDDuration51000JPY
Non operating expensesPrior1YTDDuration576000JPY
Non operating expensesCurrentYTDDuration6240000JPY
Ordinary incomePrior1YTDDuration30639000JPY
Ordinary incomeCurrentYTDDuration64211000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass